FDA Approves Inluriyo for Advanced Breast Cancer

FDA approves Inluriyo for advanced breast cancer

The U.S. Food and Drug Administration has approved Eli Lilly's Inluriyo (imlunestrant), an oral estrogen receptor antagonist, for the treatment of adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic breast cancer whose disease progressed after at least one line of endocrine therapy (ET).

FDA Approves Inluriyo for Advanced Breast Cancer

TUESDAY, Sept. 30, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Inluriyo (imlunestrant), an oral estrogen receptor antagonist, for the treatment of adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated advanced or metastatic…

FDA Approves Guardant360 Test With Inluriyo for ESR1 Breast Cancer

The FDA approved Guardant360 CDx to identify adults with ESR1-mutated, ER-positive, HER2-negative breast cancer eligible for treatment with Inluriyo.

New breast cancer drug wins FDA approval after slashing progression risk by nearly 40% – Democratic Accent

The U.S. Food and Drug Administration has approved a new treatment for advanced breast cancer. Drugmaker Eli Lilly announced on Sept. 25 the approval of Inluriyo, an oral estrogen receptor antagonist, to treat adults with specific types of the disease. Those types include estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer. WEIGHT LOSS COULD BE JUST A PILL…

FDA Approves Guardant 360 CDx With Imlunestrant in ESR1+ Breast Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA approves imlunestrant for advanced breast cancer, enhancing treatment options for patients with ESR1 mutations through innovative genomic profiling.